From the patient resilience perspective, we propose that appropriate selection and cutoff values using a fluid biomarker panel followed by a confirmative amyloid or tau PET study may be suitable to diagnose patients with AD for amyloid-modifying treatment [46,47]. Here, MAPT is linked to Alzheimer disease.